MedTrace Logo

GONAL-f CONSORT (Consistency in r-hFSH Starting Doses for Individualised Treatment)

NCT01100333 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2552

Last updated 2014-07-31

No results posted yet for this study

Summary

This non-interventional study (NIS) is planned to examine the consistency of the dose recommended by the doctor for the first stimulation day with the dose recommended by the CONSORT calculator.

Conditions

Interventions

DRUG

Recombinant human follicle stimulating hormone (r-hFSH)

Recombinant hFSH prescribed according to prescriber's judgement

Sponsors & Collaborators

  • Merck KGaA, Darmstadt, Germany

    lead INDUSTRY

Principal Investigators

  • W. Bilger · Merck Serono GmbH, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Eligibility

Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01100333 on ClinicalTrials.gov